Excess of infection with SARS-CoV-2 during the first versus second wave of the COVID-19 pandemic among patients with long COVID Authors: Charles Ouazana Vedrines, Clément Gouraud, Marc Scherlinger, Sabrina Betouche, Fabrice Carrat, Eric Caumes, Victor Pitron, Olivier Robineau, Jean Sibilia, Patricia Thoreux, Kewei Xiang, Brigitte Ranque, Cédric Lemogne, CASPer-COVID study group Published: 2025 ABSTRACT BackgroundPost-COVID-19 condition affects up to 10% of patients months after a COVID-19 episode. Population-based epidemiology suggests that self-reported long COVID in France might be more common among those infected during the first wave of the pandemic than the second one, supporting the role of contextual risk factors in symptom persistence in some patients. We aimed to examine whether this pattern could also be observed in a clinical setting, considering patients with well-characterized post-COVID-19 condition and the general population.MethodsIn a case-population study, we compared the rate of SARS-CoV-2 infection during the first wave (January 1 to May 11, 2020) versus the second wave, which involved the same historical variant (May 12, 2020 to January 15, 2021) between patients with post-COVID-19 condition assessed during a multidisciplinary day-hospital program and the general population. Binary logistic regression was used to compute odds ratio (OR) and 95% confidence interval (CI) for infection during the first versus the second wave.ResultsAmong 177 consecutive patients, the odds of reporting SARS-CoV-2 infection during the first versus the second wave were significantly higher than in the Paris area general population (OR [95% CI]: 1.74 [1.27–2.40]), p < 0.001). The results remained similar in sensitivity analyses considering the French general population (1.36 [1.02–1.88]).ConclusionsThese results further suggest the role of contextual factors in long COVID and the relevance of a biopsychosocial perspective.Keywords: Long COVID, Persistent symptoms, Post-COVID-19 condition, Risk factors, Biopsychosocial model, Multidisciplinary care Background After a COVID-19 episode, enduring and debilitating symptoms are reported by up to 10% of patients at 12 months [1, 2]. This condition, frequently referred to as ‘long COVID’ or ‘post-acute sequelae of COVID-19’ (PASC), is acknowledged by the World Health Organization (WHO) as ‘post-COVID-19 condition’ [3]. A better understanding of the risk factors involved in the development of long COVID would allow for earlier and more effective detection and treatment. For instance, the omicron variant has been associated with a lower risk of post-COVID-19 condition [4], while vaccination also reduces this risk [1, 5]. Beyond viral factors or patient characteristics [6–8], recent findings suggested that self-reported long COVID in France might be more frequent among those infected with SARS-CoV-2 during the first pandemic wave [9, 10]. In a convenience sample recruited through social media, this risk was especially high when the infection took place around the announcement of the first lockdown in France [9]. This preliminary finding was replicated in a population-based study where the adjusted relative risk of developing post-COVID-19 symptoms was 1.36 times higher when the infection occurred in the first versus the second wave, that is with the same historical variant and before vaccination [10]. Notably, this increased risk was observed across all persistent symptoms, except for anosmia, which is the only long COVID symptom specific to SARS-CoV-2 infection. These results suggest that contextual factors associated with the first wave (e.g., lockdown measures) but not directly to the virus itself may have contributed to the development of a post-COVID-19 condition in at least a proportion of patients. Examples of such contextual factors include psychosocial stress related to lockdown or changes in standards of care for severe COVID-19, which could have influenced the risk of post-COVID-19 condition in those infected. However, it remains unknown whether this observation also holds true for patients with clinically diagnosed post-COVID-19 condition who are seeking for medical help. Post-COVID-19 condition is so heterogeneous that participants from population-based studies may differ from patients encountered in clinical practice. A study in a clinical setting was thus warranted. Gathering evidence about the potential role of contextual factors, among other factors, may influence research efforts towards a more comprehensive understanding of the causes of the post-COVID-19 condition [11, 12] and provide the rationale for potential preventive and therapeutic strategies [13, 14]. In June 2021, in line with national recommendations [15], a day-hospital multidisciplinary program dedicated to patient patients with long COVID was set up in the university hospital “Hôtel-Dieu” (Paris, France). This study aimed to compare the date of SARS-CoV-2 infection in patients with a diagnosis of post-COVID-19 condition from this well-characterized clinical population versus the general population. Methods In an observational retrospective case-population study, we compared the rates of SARS-CoV-2 infection during the first (before May 12, 2020) versus the second wave (from May 12, 2020 to January 15, 2021), involving the same historical variant, between the general population and patients with post-COVID-19 condition assessed during a multidisciplinary day-hospital program. The CASPer-COVID day hospital The CASPer-COVID (Circuit Ambulatoire de prise en charge des Symptômes PERsistants post-COVID-19) program aims to provide a comprehensive assessment and personalized treatment plan to each patient presenting with persistent symptoms after a documented or self-reported infection with SARS-CoV2. CASPer-COVID is one of the few structures referenced by the health regional agency of Paris area for investigating and managing post-COVID-19 condition. Recruitments pathways were identical for patients infected during the first and second wave as the day hospital program began in June 2021, after the end of the second wave in January 2021. Patients could be referred to the program by their general practitioner or any physician participating in their care. They were asked to complete a dedicated questionnaire and to submit all relevant clinical information, including laboratory or imaging results, hospitalization reports, or consultation notes concerning COVID-19 and post-COVID-19 condition. Before admission, medical records are carefully reviewed by a senior physician and any needed supplemental exploration are planned before the day hospitalization. The first step of the day visit is a one-hour medical examination by an internist or infectious disease specialist. The second step is a psychiatric consultation with two objectives: a global psychiatric evaluation and the search for cognitive and behavioral mechanisms potentially involved in the maintenance of physical symptoms (i.e., classical conditioning, focused attention on bodily functioning, catastrophizing, avoidance of symptoms and intolerance to uncertainty). Finally, an adapted physical activity specialist assesses the physical abilities and exercise habits, as well as potential barriers to physical activity. After a multidisciplinary consultation meeting between the three specialists, participants and their treating physicians receive personalized diagnoses, recommendations and referral, if necessary. This program and information regarding evaluation and data collection has been detailed elsewhere [16]. Study population Patients admitted in our day hospital program for long COVID were included from June 18, 2021 to September 6, 2022. The inclusion criteria were to be 18 years old or older, having a diagnosis of post-COVID-19 condition at the end of the day hospital program, and having been infected with SARS-CoV-2 before January 15, 2021, that is during the first or the second wave of the pandemic. Consistent with the WHO definition, individuals were classified as having post-COVID-19 condition if they presented at least one symptom that occurred within three months of probable infection with SARS-CoV-2 and persisted for a minimum of two months, impairing daily functioning [3]. The exclusion criteria were symptoms attributed to the COVID-19 vaccine rather than SARS-CoV-2 infection and a differential diagnosis fully explaining the symptoms presented (consistent with the WHO definition of the post-COVID-19 condition). Patients with no documentation (PCR, antigenic test or serology) of SARS-CoV-2 infection were not excluded, which is consistent with the WHO definition of the post-COVID-19 condition [3]. General population Patients admitted to our day hospital were more likely to have been infected in the Paris area than elsewhere in France. Therefore, since the Paris area was one of the French regions where the incidence of COVID-19 was the highest during the first wave [17], the general population considered for comparison in the main analysis was the Paris area general population. In sensitivity analyses, we extended the analysis to the French general population. Outcomes The primary endpoint was the date of documented or self-reported first infection with SARS-CoV-2. Incidence of COVID-19 in Paris area and in France during the first and second wave Regarding the incidence of COVID-19 in the Paris area general population, estimates were obtained from a previous modelling study based on the joint analysis of age-stratified seroprevalence, hospitalization, and case data, with deconvolution methods [17]. Regarding the incidence of COVID-19 in the French general population, two sources were used. For the first wave (i.e., before May 12, 2020), a national model developed by the Pasteur Institute was used. The number of hospitalizations and deaths due to COVID-19 were considered to infer the number of cases in France during the pandemic first wave, based on data available when tests were widely available (i.e., at the end of 2020) [18]. Regarding the incidence of COVID-19 during the second wave (i.e., from May 12, 2020 to January 15, 2021), we used public governmental data regarding RT-PCR test results for SARS-CoV-2 (official and open-access public health data available at https://www.data.gouv.fr/fr/datasets/donnees-de-laboratoires-pour-le-depistage-a-compter-du-18-05-2022-si-dep/). Statistical analysis Categorical variables were presented as percentages and continuous variables with median and interquartile ranges (IQR). Pearson's chi-square tests and Kruskal Wallis’ tests were used to compare clinical data systematically assessed during the day hospital stay in patients infected during the first versus the second wave. Odds ratios (ORs) were obtained from binary logistic regressions comparing the odds of having been infected during the first (versus second) wave according to the group (day-hospital patients versus general population). The dependent variable was the wave of infection (first = 1, second = 0), and the independent variable was the group (day-hospital = 1, general population = 0). The ORs were calculated as exp(β), where β is the regression coefficient for the group variable. 95% confidence intervals (CIs) were derived from the standard error of β (i.e., exp(β ± 1.96 × SE)). No covariates were included because individual-level clinical data were unavailable for the general population; thus these ORs are unadjusted. In main analyses, we aimed to compare patients infected during the first wave (i.e., before May 12, 2020) versus the second wave (i.e., from May 12, 2020 to January 15, 2021), which involved the same historical variant, in our study population versus Paris area general population. In a sensitivity analysis, we extended the analysis to the French general population. All analyses were performed using R software, version 4.0.3, with a threshold for statistical significance at two-sided p < 0.05. Results Participants A total of 301 patients had attended the CASPer-COVID program on September 6, 2022. Twenty-five were referred for persistent symptoms not attributed to COVID-19 and were excluded (e.g., post vaccination symptoms). This study included 276 patients (70.0% women, median age [IQR]: 44 years [34–55]) with a diagnosis of post-COVID-19 condition. The characteristics of this population, including medical record conclusions, have been described elsewhere [16]. A total of 113 patients reported an initial infection between January 1, 2020 and May 11, 2020 (i.e., first period; 131 days), 64 between May 12, 2020 and January 15, 2021 (i.e., second period for the main analysis; 249 days). Therefore, a total of 177 (113 + 64) patients were included in the main analysis (Fig. 1). Table 1 displays the characteristics of participants infected during the first versus the second wave. Patients reporting infection during the first wave were more likely to present with shortness of breath (76.1% versus 57.8%, p = 0.01) and chest pain (55.2% versus 34.9% p = 0.03), and had a greater duration of symptom evolution (median of 640 vs 427 days, p < 0.01). There were no other statistically significant differences between the two groups. Flow chart Table 1Characteristics of the study population according to the period of infectionFirst wavea(n = 113)Second waveb(n = 64)Continuous variablesMedian (IqR)pAge46 (37–56)44 (30.5–55.5)0.17SF-36 Mental Component (n = 144)47 (35–62)44 (37–58)0.54SF-36 Physical Component (n = 144)40.5 (34–50)38 (29–51)0.56Sickness absence (months) (among workers; n = 88)5 (2–12)6 (2–11)0.74Pichot fatigue scale (n = 161)23 (18–28)24 (21.5–26)0.90HAD-A scale (n = 155)8 (5–12)8 (5–11)0.57HAD-D scale (n = 157)7 (5–12)8 (5–11)0.70SSD-12 scale (n = 160)26.5 (21.5–34)27.5 (17.5–32)0.67Ricci & Gagnon physical activity scale (n = 147)16 (11–26)14.5 (10–24)0.32Duration of symptoms evolution (in days)640 (546–753)427 (319–544) < 0.01Categorical variablen (%)pGender (women)81 (71.7)44 (68.8)0.68Medical conclusions Depressive disorder (n = 168)35 (33.0)17 (27.4)0.45 Anxiety disorder (n = 168)24 (22.4)12 (19.7)0.68 Positive arguments for a functional somatic disorder* (n = 170)90 (82.6)54 (80.3)0.71 Somatic explanation for the persistent symptoms (n = 174)12 (10.7)5 (8.06)0.57 Recommendation of physical rehabilitation (n = 165)96 (90.6)141 (91.5)0.66Persistent symptoms Fatigue (n = 177)97 (85.8)58 (90.6)0.935 Shortness of breath (n = 177)86 (76.1)37 (57.8)0.01 Joint/muscular pain (n = 174)70 (63.1)37 (58.7)0.57 Cognitive dysfunction (n = 177)71 (62.8)41 (64.1)0.87 Palpitations (n = 176)47 (41.6)30 (47.6)0.44 Chest pain (n = 176)59 (52.2)22 (34.9)0.03 Headache (n = 177)39 (34.5)28 (43.8)0.22 Digestive symptoms (n = 177)43 (38.1)26 (40.6)0.74Acute episode severity (n = 176) Hospitalisation18 (15.9)6 (9.5)0.24 Oxygen therapy7 (6.2)1 (1.6)0.16 Intensive Care Unit5 (4.4)1 (1.6)0.32Percentages are calculated based on the number of available observations in each wave. The n = after each variable name indicates the total available observations for that variable (sum of the two wave-specific denominators n1 for the first wave and n2 for the second wave). Denominators vary across variables due to missing dataHAD-A Hospital Anxiety and Depression-Anxiety subscale; HAD-D Hospital Anxiety and Depression-Depression subscale; IqR interquartile range; SSD-12 12-item Somatic Symptom Disorder B criteria scale, assessing psychological burden associated with peristent symptoms; SF-36 36-item Short-Form Health survey questionnaire, assessing health-related quality of lifeaBefore May 12, 2020bBetween May 12, 2020 and January 15, 2021*Classical conditioning, focused attention on bodily functioning, catastrophizing, avoidance of symptoms, and intolerance to uncertainty Characteristics of the study population according to the period of infection Percentages are calculated based on the number of available observations in each wave. The n = after each variable name indicates the total available observations for that variable (sum of the two wave-specific denominators n1 for the first wave and n2 for the second wave). Denominators vary across variables due to missing data HAD-A Hospital Anxiety and Depression-Anxiety subscale; HAD-D Hospital Anxiety and Depression-Depression subscale; IqR interquartile range; SSD-12 12-item Somatic Symptom Disorder B criteria scale, assessing psychological burden associated with peristent symptoms; SF-36 36-item Short-Form Health survey questionnaire, assessing health-related quality of life aBefore May 12, 2020 bBetween May 12, 2020 and January 15, 2021 *Classical conditioning, focused attention on bodily functioning, catastrophizing, avoidance of symptoms, and intolerance to uncertainty Incidence of COVID-19 in Paris area and French general population during the first versus the second wave 13.3% of the population of the Paris area (N = 1,633,002) were estimated to have had a SARS-CoV-2 infection by May 11, 2020, compared to 13.2% (N = 1,620,724), between May 12, 2020 and January 15, 2021 [17]. For the sensitivity analysis with extension to the French general population, 5.3% of the French population (N = 3,551,000) were estimated as having been infected with SARS-CoV-2 by May 11, 2020 [18], while about 4.1% (N = 2,742,678) were infected by SARS-CoV-2 between May 12, 2020 and January 15, 2021 [19]. Date of first infection in the study population compared to the general population The odds of having been infected during the first versus the second wave was significantly higher in the study population than in the Paris area general population (OR [95% CI]: 1.74 [1.27–2.40], p < 0.001). In sensitivity analyses with extension to the French general population, the odds of having been infected during the first versus the second wave remained higher in the study population than in the general population (OR [95% CI]: 1.36 [1.02–1.88], p = 0.049). Discussion In this observational retrospective study of 177 adults with a diagnosis of post-COVID-19 condition after a day-hospital dedicated to long COVID between June 2021 and September 2022, the odds of having been infected during the first versus the second wave of the pandemic was higher than in the general population. These findings from a clinical population replicate and extend those of a study based on participants with self-reported long COVID recruited through social media and those of a population-based study [9, 10]. Although we cannot formally exclude that few patients were involved in more than one study, there was likely no overlap at all between the three samples. All together, these results suggest that contextual factors may play a role in the risk of long COVID. Strengths of our study include the clinical diagnosis of post-COVID-19 condition in the study population and the reliance on two different samples for the control group, including the French general population. In addition, we restricted our analysis to the first and second wave of the pandemic, so that our results could not be explained by virus variants or vaccination. Some limitations should be considered. First, our sample included patients consulting in a tertiary center for long-lasting symptoms associated with severe functional impairment, and is therefore not representative of all patients presenting with long COVID. However, as stated in the introduction, since such difference between the first and the second wave was already confirmed in a population-based study with multi-adjusted analysis, our aim was precisely to replicate this observation in a clinical setting, that is in patients with clinically diagnosed long COVID who are seeking medical help. Furthermore, results from the sensitivity analyses extended to the French general population were strikingly similar to those obtained in a French population-based study with analyses adjusted for several confounding factors [10], as well as to findings from a multi-adjusted Japanese study [20], supporting the external validity of our results. Second, no clinical data were available for the general population so that only non-adjusted analyses were performed. Therefore, our results might be partially explained by confounding factors, which is a common issue in long COVID research [21]. However, confounding factors would be factors related to both having been infected during the first wave and having developed post-COVID-19 condition. Risk factors for having been infected during the first wave include male gender, older age, belonging to an ethnic minority, low socioeconomic status, larger household size, lower income level, inability to work remotely, reliance on public transportation, and working as a healthcare professional [22–24]. Risk factors for long COVID include female gender, belonging to an ethnic minority, low socioeconomic status, smoking, obesity, and premorbid medical conditions including prior psychiatric disorders [5, 25]. Therefore, belonging to an ethnic minority or experiencing socioeconomic deprivation could partially explain our findings. However, although we did not collect socioeconomic data (and ethnic data are restricted by law in France), these factors are unlikely to characterize our clinical population, which consists of patients with sufficient resources and health literacy to access tertiary care [26–28]. Third, the date of infection in our study population was partially self-reported and memory bias may have occurred, while infection may not have been documented. Fourth, a small proportion of the French general population may also have a post-COVID-19 condition. Fifth, consistent with the WHO definition of the post-COVID-19 condition, we did not exclude patients who reported a SARS-CoV-2 infection without test results. Consequently, individuals experiencing persistent symptoms without SARS-CoV-2 infection could have been included in our study. Since testing was not available during most of the first wave in France, this would have excluded a large proportion of patients during this first period. Sixth, the durations of the two waves differed: the first wave lasted approximately 4.5 months, and the second wave approximately 8 months. However, as the duration difference applied equally to the populations compared, it is unlikely to have influenced our findings regarding differences between groups. Finally, regarding the number of infections in the general population, a small proportion could be re-infections despite the short period of time, especially in the main analysis. Various hypotheses may explain these results. First, since our day-hospital program is a tertiary care university hospital program, the time lapse between the development of persistent symptoms and the attendance of the day-hospital could have led to an over-representation of patients infected earlier in the pandemic. However, our program opened in June 2021 only (i.e., more than one year after the beginning of the pandemic). Since post-COVID-19 persistent symptoms tend to spontaneously wane over time [1], one may have expected recently infected patients to be overrepresented. Our study might indeed have underestimated the association of long COVID with an infection during the first wave. Second, improvements in the management of severe forms of COVID-19 between the first and second waves of the pandemic may have reduced the risk of developing long-term mental and physical sequelae following infection [29, 30]. However, given the small proportion of patients hospitalized for COVID-19 in our sample (i.e., 13%), this is unlikely to fully account for our findings. Furthermore, in a French population-based study with analyses adjusted for several confounding factors, the reduction in the risk of post-COVID-19 symptoms after the first wave persisted after adjustment for indicators of acute infection severity and was also observed in people with no history of COVID-19-related hospitalization [10]. Third, the present results may also be explained by contextual factors, such as psychosocial factors differentiating the first and the second waves. The first wave of the COVID-19 pandemic was arguably an unprecedented period of stress worldwide. From March 17th to May 11th 2020, the French general population was facing a strictly enforced lockdown, confusing and scary information about the lethality and the rapid spreading of the virus all over the world, limited biological testing, lack of protection gear (i.e., masks), and saturation of intensive care units. In addition, reduced levels of physical activity and increased rates of familial violence have also been reported during the lockdown [31, 32]. High levels of uncertainty and health-related concerns in this period may have increased the risk of persistent symptoms by increasing psychological distress [33–35], fostering negative expectations about symptoms [36, 37], or focusing attention on bodily functioning [38]. Of note, the persistent symptoms that were more frequent among patients infected during the first wave (i.e., shortness of breath and chest pain) were those that were mostly feared during the first wave. These psychosocial mechanisms may have increased the risk of persistent physical symptoms after COVID-19, as it is frequently observed in other conditions [39]. Importantly, these mechanisms should not be opposed to viral factors and may indeed interact with physical symptoms triggered by an acute infection [11, 12]. Conclusion The odds of having been infected with SARS-CoV-2 during the first wave versus the second wave was higher in patients with established post-COVID-19 condition than in the general population. This finding replicates and extends, in a clinical setting, the results of two previous studies in a convenience sample of participants with self-reported long COVID and in a population-based study [9, 10]. These consistent results add to the increasing amount of evidence suggesting the role of contextual factors in the development of long COVID and the relevance of a biopsychosocial perspective, for both clinical practice and public health. Acknowledgements Not applicable. CASPer-COVID Study Group The CASPer-COVID Study Group eleven infectious diseases specialists (M. Belan, D. Batisse, E. Canoui, E. Caumes, M. Karmochkine, P. Parize, A. Pouvaret, J. Pavie, A. Serris, L. Slama, J-P. Viard), thirteen internists (J-B. Arlet, G. Cheminet, E. Flammarion, P. Getten, A. Kachaner, E. Lafont, C. Manoli, A. Michon, B. Ranque, N. Senot, O. Steichen, J. Tennebaum, A. Vanjak), one general physician (K. Xiang), four adapted activity specialists (K.Bolloch, V.Goyat, E. Lerondeau, C.Verot), one sports medicine physician (P.Thoreux) and seven psychiatrists (J. Dubois, C. Gouraud, C. Lemogne, C. Ouazana Vedrines, C. Pritschkat, V. Pitron, L. Rotenberg). Authors’ contributions COV and CL designed the study; COV, CG, BR, CL, and VP worked on literature search; COV, SB, CG, PT, BR, CL and KX contributed to collection and assembly of data; COV, CG, CL, BR, EC, OR, JS and FC contributed to data analysis and interpretation; COV, CG and VP provided technical support. All authors have contributed to interpretation and critically reviewed the manuscript. All authors approved the final version of the manuscript. Funding No funding declaration. Data availability The datasets generated during and/or analyzed during the current study are not publicly available due to legal reasons related to data privacy protection in the context of usual care. Declarations Ethics approval and consent to participate This retrospective study was designed in accordance with the declaration of Helsinki. After confirming that the intended research did not involve human subject as defined by the French law n◦2012–300 of March 5, 2012, regarding research involving human subjects, the project received authorization from the “Comité d’éthique de la recherche AP-HP Centre” (CERAPHP); IRB registration #00011928, Ref 2022-10-08. Specifically, as this study was a restrospective chart review observational study, written consent was not required. Nevertheless, participants were informed that medical records could be used for research purposes via the medical examination report they received after their participation. They were also informed of the procedure to follow should they wish to oppose the use of their data for research purposes. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Brigitte Ranque and Cédric Lemogne contributed equally to this work. Contributor Information Charles Ouazana Vedrines, Email: charles.ouazana-vedrines@aphp.fr. CASPer-COVID study group: Martin Belan, Dominique Batisse, Etienne Canoui, Marina Karmochkine, Perrine Parize, Anne Pouvaret, Juliette Pavie, Alexandra Serris, Laurence Slama, Jean-Paul Viard, Jean-Benoit Arlet, Geoffrey Cheminet, Edouard Flammarion, Prunelle Getten, Emmanuel Lafont, Corina Manoli, Adrien Michon, Noémie Odette Senot, Olivier Steichen, Juliette Tennenbaum, Anthony Vanjak, Katell Bolloch, Vincent Goyat, Emma Lerondeau, Corentin Verot, Julie Dubois, Caroline Pritschkat, Léa Rotenberg, and Alexandra Kachaner References Associated Data Data Availability Statement The datasets generated during and/or analyzed during the current study are not publicly available due to legal reasons related to data privacy protection in the context of usual care.